IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

Core Insights - Iradimed Corporation reported record revenue of $19.5 million for Q1 2025, an 11% increase year-over-year, and a 16% rise in diluted EPS [3][6][8] - The company declared a regular quarterly cash dividend of $0.17 per share, reaffirming its commitment to shareholder value [5][3] - Financial guidance for Q2 2025 includes expected revenue of $19.7 million to $19.9 million and GAAP diluted EPS of $0.37 to $0.40 [4][11] Financial Performance - For the three months ended March 31, 2025, revenue was $19.5 million, up from $17.6 million in Q1 2024, marking an 11% increase [6][8] - Net income for the same period was $4.7 million, a 15% increase from $4.1 million in Q1 2024, resulting in diluted EPS of $0.37, up 16% [6][31] - Non-GAAP net income was reported at $5.3 million, excluding stock compensation expenses, reflecting a 15% increase year-over-year [7][31] Revenue Breakdown - Revenue from MRI compatible IV infusion pump systems was $5.999 million, and from patient vital signs monitoring systems was $6.545 million, contributing to a total devices revenue of $12.962 million [9] - Domestic sales accounted for 82% of total revenue, an increase from 76% in the same period of 2024 [9] Cash Flow and Expenditures - Cash flow from operations for Q1 2025 was $4.3 million, a 10% increase from $3.9 million in Q1 2024 [10] - The company anticipates spending approximately $3.0 million on its new manufacturing facility in Orlando, Florida, expected to be completed in July 2025 [10] Future Guidance - For Q2 2025, the company expects revenue between $19.7 million and $19.9 million, with GAAP diluted EPS projected at $0.37 to $0.40 [4][11] - Full-year 2025 guidance remains unchanged, with expected revenue of $78.0 million to $82.0 million and GAAP diluted EPS of $1.55 to $1.65 [4][11]